Srs Capital Advisors, Inc. Myriad Genetics Inc Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 17,485 shares of MYGN stock, worth $117,324. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,485
Previous 454
3751.32%
Holding current value
$117,324
Previous $2,000
6200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding MYGN
# of Institutions
238Shares Held
92.1MCall Options Held
86.1KPut Options Held
18.9K-
Black Rock Inc. New York, NY15.2MShares$102 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.88MShares$52.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.98MShares$33.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.75MShares$31.9 Million0.02% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$30.8 Million0.75% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $541M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...